Pituitary gonadotropes synthesize and secrete follicle-stimulating hormone (FSH). FSH is a heterodimer that consists of an α-and β-subunit. The α-subunit is common to other pituitary and placental glycoprotein hormones, and the β-subunit is the hormone/receptor-specific subunit. Although the pituitary is the main tissue that accounts for circulating hormone, previous and recent reports indicate extra-pituitary sources of FSH production including mouse gonads, human stomach, prostate, umbilical cord vein endothelial cells, uterine myometrium, placenta, and chicken abdominal adipose tissue. Whether extra-pituitary derived FSH exerts any physiologically significant actions is not known. In this review, we have comprehensively analyzed the expression of mRNAs that encode mouse and human FSH subunits and also their corresponding expressed sequence tags in normal tissues, cancer cell lines, and primary tumors by public database mining. We propose criteria to assess the significance of individual FSH subunit or FSH dimer expression as well as genetic approaches to unambiguously define the physiological relevance of extra-pituitary FSH expression.
Introduction
Follicle-stimulating hormone (FSH) is a heterodimeric glycoprotein synthesized in pituitary gonadotropes [1] [2] [3] . It consists of two subunits, an α-and β-subunit. The α-subunit is common to other pituitary and placental glycoprotein hormones including luteinizing hormone (LH), thyroid stimulating hormone, and human chorionic gonadotropin (hCG), which is an LH analog [1] [2] [3] . The β-subunits are hormone-specific and noncovalently assembled with the α-subunit to form heterodimers. The subunits are encoded by distinct genes and are regulated by hypothalamic gonadotropin releasing hormone, gonadal steroids and gonadal/gonadotrope peptides, activins, and inhibins [1] [2] [3] . Transcriptional regulation of FSH subunits has been extensively studied in vitro using immortalized mouse gonadotrope cell lines and in vivo using genetically engineered mouse models [4] . A cascade of events regulated by the combinatorial action of several general and gonadotrope-specific transcription factors ultimately results in production of mRNAs encoding FSH subunits [4, 5] . The FSH heterodimer is constitutively secreted from gonadotropes in many vertebrates [6] . In the female, FSH binds to G protein-coupled follicle-stimulating hormone receptors (FSHR) on ovarian granulosa cells [7] [8] [9] [10] [11] . In the male, FSH binds to FSHRs on Sertoli cells in the testis [12] [13] [14] . FSH plays a pivotal role in reproductive physiology by regulating gonadal growth and differentiation, production of sex steroids, and gametes [15] . Binding of FSH to its cognate FSHRs results primarily in cAMP production and activation of the PKA signaling pathway, although a number of other signaling pathways have also been implicated in FSH signaling [7] . The FSH ligand-mediated signaling via FSHR pathway plays a significant role in female fertility, because female mice lacking the FSH ligand [7] or the FSHR [16] are sterile as a result of a preantral stage block in ovarian folliculogenesis. In contrast, male mice lacking either FSH ligand or FSHR display a decrease in testis size, as well as reduced sperm number and motility, but demonstrate normal to subfertility [15, 16] . The Fshb null mutant mice retain normal FSH responsiveness and can be rescued either pharmacologically with exogenous FSH [15] or genetically with gonadotrope-targeted expression of HF-SHB transgenes [6] . Both the FSH ligand-and FSH receptor-deficient mice closely phenocopy women carrying inactivating mutations in the gene encoding human FSHR [5, [17] [18] [19] [20] [21] [22] , although men with impaired FSH signaling demonstrate variable fertility phenotypes [5, [17] [18] [19] [20] [21] [22] . Patients carrying mutations in human FSHB have also been identified and characterized, although these cases are relatively rare [18] [19] [20] 22] .
Although most pituitary tumors from gonadotrope origin are classified as nonfunctional adenomas, FSH-secreting gonadotrope tumors have been identified in both women and men [23, 24] . Most often, high FSH levels in these patients result in ovarian hyperstimulation and cyst formation. In men with FSH-secreting functional adenomas, hypogonadism as well as hyperandrogenemia were reported [23, 24] . The molecular basis for this hormone-secreting versus nonsecreting phenotype remains unknown.
Ectopic expression of follicle-stimulating hormone subunits or follicle-stimulating hormone dimer in normal physiology and pathological conditions Although the pituitary is the major tissue known to express FSH, several studies indicate that individual subunits are ectopically expressed in nonpituitary tissues under both physiological and pathological conditions. For example, Markkua et al. used RT-PCR and Southern blot techniques and found that Cga and Fshb mRNAs were expressed in mouse ovaries [25] . The same group subsequently reported that the mRNAs encoding FSH subunits were also expressed in mouse testis [26, 27] . They performed northern blot analysis and used immunohistochemistry to show that the subunits are localized within mouse testis [26, 27] . Mandrekar et al. identified immunoreactive FSH in human gastric mucosa and purified FSH-like material from this tissue that co-eluted with 125 I-FSH on gel filtration columns [28] . In human prostate, expression of FSH was identified by RT-PCR, Southern blot, and gel filtration analyses [28] . In chicken abdominal adipose tissue, FSH protein was reported to be expressed, although surprisingly in the absence of any RNA expression as measured by RT-PCR [29] . In conjunction with their expression studies on extra-gonadal FSHRs and their actions in nongonadal tissues, Stilley et al. recently reported that CGA and FSHB mRNAs were expressed in human placenta, uterus, and cultured human umbilical vein endothelial cells and suggested an autocrine mechanism of action for locally produced FSH [30] [31] [32] . Differential expression of gonadotropin subunits, particularly mRNAs encoding the hCG subunits, was previously identified in several human cancer cell lines and primary tumors [33] . Of the 1036 cancer cell lines analyzed (data extracted from Entrez 2012-10-18.res: Gene-centric RMA-normalized mRNA expression data and queried from University of Texas Houston website), high level expression of CGA mRNA was noted in breast, CNS, liver, lung, ovary, pancreas, skin, stomach, and thyroid cancer cell lines. Low level expression was also found in cell lines derived from hematopoietic/lymphoid tissue, and large intestine. In contrast, FSHB displayed more variable expression levels in the same cell lines tested as above. For example, of the 59 breast cancer cell lines listed, 21 showed elevated expression and 29 showed reduced expression of FSHB. Similarly, of 12 thyroid cancer cell lines tested, 7 showed elevated and 5 showed reduced expression of FSHB.
When CGA expression was analyzed in primary tumors, the majority of the primary tumors showed elevated expression comparted to the corresponding normal tissue, closely matching the data for cancer cell lines. In sharp contrast, out of the 8 tumor types analyzed, only 3 types of primary tumors (breast, lung, and lung squamous) displayed elevated FSHB expression. In the remaining 5 primary tumors, elevated FSHB expression was significantly suppressed compared to the corresponding normal tissue. Thus, although mRNAs encoding FSH subunits are expressed in cancer cell lines and primary tumors, the functional significance of such ectopic expression has not been tested. Moreover, it is also unknown whether a functional FSH heterodimer is assembled and secreted from these cell lines or from primary tumors.
In silico expression analysis of expressed sequence tags/RNAs encoding mouse and human follicle-stimulating hormone subunits
To further investigate whether FSH is indeed expressed in tissues other than the pituitary, we queried the in silico electronic PCR database (https://www.ncbi.nlm.nih.gov/ UniGene/ESTProfileViewer). We analyzed multiple tissues and noted the expression levels and relative abundance of expressed sequence tags (ESTs) representing RNAs encoding FSH subunits in mouse (Cga and Fshb) and human (CGA and FSHB) ( Tables 1 and 2 ). Of the 47 mouse tissues analyzed for ESTs representing Cga, the pituitary gland showed the expected high level expression (830 units). Surprisingly, embryonic tissue was the only other tissue reported to express Cga (23 units). Similarly, of these same mouse tissues, Fshb showed the highest level of expression in pituitary (4150 units) compared to embryonic tissue (13 units) and brain (2 units) .
When compared to the expression of mouse Cga, human CGA was more broadly expressed. In addition to pituitary and placenta, we found that CGA was expressed in 12 other tissues including, in order of expression, ear (931 units), stomach (167 units), thyroid (128 units), connective tissue (87 units), vascular tissue (58 units), heart (33 units), embryonic tissue (23 units), muscle (18 units), lung (11 units), total brain (6 units), mammary gland (6 units), and liver (4 units). As expected, both pituitary and placenta showed the highest levels of expression with 12 223 units and 2452 units, respectively. We found that the expression of human FSHB was more restricted in contrast to that of CGA. FSHB was ectopically expressed at low In all other mouse tissues both subunits not detected levels in three tissues including vascular tissue (58 units), testis (9 units), and whole brain (2 units). As expected, the pituitary gland showed the highest level (484 units) of expression compared to the other three nonpituitary tissues. Interestingly, co-expression of FSH subunits was only identified in embryonic tissue in mice, and only in whole brain and vascular tissue in humans. Even when co-expression was observed, the expression of FSH subunits was very low in the three ectopic tissues (mouse embryonic tissue, human brain, and human vascular tissue).
Limitations to the published studies on ectopic expression of follicle-stimulating hormone subunits
In light of the above in silico data, studies that have reported ectopic expression of FSH subunits have several limitations. In studies by Markkula et al., there was neither immuno-localization data nor further functional characterization of gonadal expression of rat FSH subunits [25, 26] . In one study, although FSH subunits were reported to be expressed in various testicular germ and somatic cells, the existence and physiological significance of a functional FSH dimer was not made clear [26] . In the study by Mandrekar et al., one problem appears to be the use of relatively uncharacterized and impure antibodies [34] . Similarly, RT-PCR and immunochemical analyses were used to identify FSH expression in the human prostate study [35, 36] . A serious limitation with the reported ectopic expression of FSH in chicken abdominal adipose tissue is the absence of identity of the subunit that was analyzed by RT-PCR [29] . Moreover, this study In all other human tissues both subunits not detected reported FSH protein localization in the absence of any FSH subunit mRNA expression in the chicken adipose tissue. In studies by Stilley et al., only RT-PCR was employed using primers that span exon 2 and 3. Very weak expression of FSHB mRNA was noted in many of the human tissues examined in this study [30] . Whether full length CGA and FSHB cDNAs were amplified from or 125 I-FSH binding to these ectopic tissues was not tested. Moreover, the molecular identity and the physiological concentrations of an FSH heterodimer in these tissues was also not directly tested.
The physiological significance of the extra-pituitary FSH expression is not clear. The circulating levels of FSH are easily accessible to many of the extra-pituitary tissues reported to locally synthesize FSH. One key question that emerges is the likely differences in regulation of locally produced FSH compared to pituitary-derived FSH. However, to date no such new regulatory mechanism that controls local production of FSH in extra-pituitary tissues has been identified. It is also important to use multicenter validated reagents in establishing extra-gonadal action of FSH, since based on a recent study [37] , the previously published reports of FSH action in various tissues including tumor blood vessels [38] need to be reevaluated.
A list of criteria to ascertain the significance of ectopic expression of follicle-stimulating hormone dimer Based on our comprehensive analyses of public gene expression databases and published reports as described above, we suggest the Downloaded from https://academic.oup.com/biolreprod/article-abstract/97/4/622/4209237 by OUP site access user on 08 October 2018 following six criteria be used to ascertain if FSH is expressed in tissues other than the pituitary. First, at least three independent expression methods including real time qPCR, western blot analysis, and immunochemistry must be employed to confirm that both the α-and β-subunit encoding mRNAs and their protein products are co-expressed in a nonpituitary tissue. Second, western blot analysis under nonreducing conditions must be employed to confirm that FSH heterodimers are indeed assembled in the nonpituitary tissue of interest. Third, immunoreactive FSH must be quantified by ELISA/RIA to confirm that sufficient amounts (at least comparable to that in pituitary of a given species) are expressed and are detectable. Fourth, the site of action of the extra-pituitary FSH must be identified. For example, it must be determined whether extra-pituitary FSH acts in an autocrine manner, acting locally on the same cells that produce it, or in a paracrine manner, acting on neighboring cells. Furthermore, irrespective of whether extra-pituitary FSH acts in an autocrine or a paracrine manner, the target of FSH action, must be determined by establishing which cell types express the cognate FSHR and which cells produce biologically active FSH as measured by a bioassay. Fifth, it must be monitored whether the addition of recombinant FSH at a physiological concentration to cultured FSHR-expressing extrapituitary target cells, must result in regulation of known/putative FSHR-mediated downstream signaling events. Criteria 4 and 5 are particularly relevant in the context of the recently reported expression of extra-gonadal FSH receptors on various mouse and human tissues [30] [31] [32] and chicken adipose tissue [29] . Sixth and finally, any claim that FSH is expressed in extra-gonadal tissues must be independently confirmed in different laboratories. It is interesting to note that the extra-gonadal FSHR expression in some human tissues has also recently been challenged [37] .
Conclusions and future directions
In light of several recent reports of expression of extra-gonadal FSHRs in various mouse and human tissues [30] [31] [32] 39] , it becomes critical to identify which of these tissues also locally express FSH heterodimer. This issue is important, because of the proposed endocrine/paracrine/autocrine actions of FSH in different tissues while mechanisms of pituitary regulation may not be present locally in extra-pituitary tissues. A comprehensive analysis of expression of mRNAs encoding mouse and human FSH subunits using normal tissues, over 1000 human cancer cell lines and several primary human tumors indicates no definitive evidence for co-expression of FSH subunit encoding mRNAs or FSH dimer in quantifiable physiologically relevant amounts. Thus, the published reports claiming expression of extra-pituitary FSH must be extensively verified based on the criteria defined in this review and cautiously interpreted. A more rigorous biochemical approach must be employed to definitively establish that FSH heterodimers are actually assembled and detected in measurable amounts in these extra-pituitary tissues. It is however intriguing to note that only individual subunits are expressed in some tissues and whether they get secreted or exert any local actions in those tissues need to be determined in future. Alternatively, similar to that suggested for determining the in vivo role of extra-gonadal FSHRs, it is highly desirable to create cell-specific knockout mouse models for the Fshb allele ("floxed" Fshb). Such Fshb flox allele bearing mutant mice could then be manipulated either spatially, temporally, or spatio-temporally and the consequences of loss of FSH assessed in these extra-pituitary tissues in a physiological context.
